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Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most
common chronic autoimmune neuropathy. While both cell-mediated and
humoral mechanisms contribute to its pathogenesis, the rapid clinical response
to plasmapheresis implicates a circulating factor responsible for peripheral nerve
injury. We report that treatment-na€ıve patients with CIDP show increased
serum and CSF levels of the anaphylatoxin C5a and the soluble terminal com-
plement complex (sTCC). Systemic terminal complement activation correlates
with clinical disease severity as determined by the Inflammatory Neuropathy
Cause and Treatment (INCAT) disability scale. These data indicate that com-
plement activation contributes to peripheral nerve injury and suggest that com-
plement inhibition should be explored for its potential therapeutic merit in
CIDP.
Introduction
Chronic inflammatory demyelinating polyneuropathy
(CIDP) is the most prevalent chronic autoimmune neu-
ropathy and the most common autoimmune-mediated
disease of the peripheral nervous system.1,2 Both cell-
mediated and humoral mechanisms contribute to its
pathogenesis and the rapid clinical response to plasma-
pheresis therapy implicates a circulating factor responsible
for peripheral nerve tissue injury in patients with CIDP.1,2
Consistent with this hypothesis, complement-fixing IgG
and IgM deposits are found on the myelin sheath in sural
nerve biopsies from patients with CIDP.3,4 Furthermore,
sera derived from patients who responded well to plasma
exchange were shown to induce demyelination and reduc-
tion of conduction velocity if adoptively transferred to
nonhuman primates or intraneurally injected into rat
sciatic nerves.5,6 Most patients with CIDP lack detectable
titers of antibodies specific for major compact myelin
proteins which suggests that serum constituents other
than myelin-directed antibodies, such as noncompact
myelin-specific antibodies, cytokines, or components of
the complement cascade might contribute to peripheral
nerve injury.1,2,7
Complement activation has long be thought to consti-
tute a potential pathogenic mechanism in CIDP since
the complement component C3d was found deposited
on the outer surface of Schwann cells and the compact
myelin in biopsies from CIDP patients.3,4 Its proinflam-
matory function is reflected by the ability of terminal
complement components such as C5a to recruit myeloid
cells such as macrophages to sites of inflammation
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through complement receptors and in inducing tissue
injury through formation of the terminal complement
complex (TCC), that is, membrane attack complex.
Koski and colleagues reported that serum TCC levels
are increased in patients with Guillain–Barre syndrome
(GBS), decline with clinical improvement and become
undetectable 1 month after onset of symptoms.8 They
also reported elevated TCC serum levels in six out of
seven patients diagnosed with chronic recurrent polyneu-
ritis8. In patients with GBS, membrane bound TCC
components were found to be deposited on the abaxonal
Schwann cell surface8,9. Hartung et al. reported elevated
C3a und C5a CSF levels in patients with GBS if com-
pared to patients with noninflammatory neurological
diseases.10 We could previously show that the presence
of serum IgG antibodies enriched for IgG-Fc glycovari-
ants that efficiently activate the complement cascade is
associated with disease activity in patients with CIDP.11
Here, we hypothesized that complement activation is




Samples and clinical data were collected between 2010
and 2015 at the Department of Neurology, University of
Marburg, Germany. All patients with CIDP fulfilled the
European Federation of Neurological Societies/Peripheral
Nerve Society (EFNS/PNS) diagnostic criteria 12 and were
newly diagnosed with an interval between onset of symp-
toms and blood/CSF draw of <3 months.
Patients showed symmetrical, proximal and distal sen-
sory and motor deficits and were therefore classified as
idiopathic/typical CIDP. Control samples were collected
from 29 patients with noninflammatory neurological dis-
ease conditions (tension-type or hypertension-induced
headache, movement disorders, stenosis of the lumbal
spinal canal, noninflammatory polyneuropathies). Sera
from patients with systemic lupus erythematosus (SLE)
were collected in 2016 at the Department of Rheumatol-
ogy and Clinical Immunology, Charite Universit€atsmedi-
zin Berlin, Germany. All patients met the updated and
revised criteria proposed by the American College of
Rheumatology (ACR) for the diagnosis of SLE13 and
received immunomodulatory therapy at the time of blood
draw (Table 1). After blood draw, serum was separated
by centrifugation at 4°C and immediately frozen at
80°C within 30 min of venipuncture. CSF collected
from both patients with CIDP and controls was also fro-
zen within 30 min of collection and stored at 80°C. To
assess treatment response, the modified INCAT score 14,15
was used routinely before and 4 weeks after IVIG-treat-
ment (Gamunex-C (Grifols) and Privigen (CSL Behring);
2 g/kg body weight over 5 consecutive days). The study
was approved by the local Institutional Review Boards
and all subjects provided informed consent.
ELISA
C5a and TCC levels in serum and CSF samples were
quantified by ELISA (Tecomedical AG, Sissach, Switzer-
land) according to the manufacturer’s recommendations.
CSF indices for C5a and sTCC were calculated as follows:
(C5a or sTCCCSF/C5a or sTCCserum)/(albuminCSF/albu-
minserum).
Statistics
Protein expression levels in serum and CSF samples were
compared using the nonparametric Mann–Whitney U
test. Correlation analyses were performed using the Spear-
man’s rank correlation coefficient. A P < 0.05 was
Table 1. Demographic an clinical characteristics of CIDP patients and
their controls.
CIDP n = 21 Controls n = 29 SLE n = 251








Male to female ratio 1.3 1.3 0.09
Fulfilling modified
AAN criteria, n; %
21; 100 NA NA
Fulfilling EFNS/PNS
criteria, n; %
21; 100 NA NA
Clinical course NA NA
CP, n; % 19; 90.5 – NA
Monophasic2, n; % 2; 9.5 – NA
CIDP subtype NA NA
CIDP-I, n; % 19; 90.5 – NA
CIDP-MGUS, n; % 2; 9.5 – NA
Treatment
response3, n; %
16; 80 NA NA
AAN, American Academy of Neurology; CP, chronic progressive; CIDP,
chronic inflammatory demyelinating polyneuropathy CIDP-I, idiopathic
CIDP; CIDP-MGUS, CIDP with monoclonal gammopathy of uncertain
significance; EFNS, European Federation of Neurological Societies; NA,
not applicable; PNS, Peripheral Nerve Society; SD, standard deviation;
SLE, systemic lupus erythematosus.
1All patients with SLE received immunomodulatory/immunosuppres-
sive treatment such as belimumab (n = 9/25), a monoclonal antibody
targeting the soluble human B lymphocyte stimulator protein BLyS,
low-dose glucocorticosteroids (n = 21/25), azathioprine (n = 21/25),
low-dose methotrexate (n = 3/25), mycophenolate mofetil (n = 3/25),
and cyclosporine (n = 1/25).
2But no Guillain–Barre syndrome.
3Defined as ≥1 point decrease in the modified Rankin’ scale. No
pretreatment data was available for one patient.
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considered significant. All graphs and statistics were done
using GraphPad Prism 5 (GraphPad Software, Inc.; La
Jolla, CA).
Results
A total of 21 newly diagnosed and treatment-na€ıve
patients with CIDP fulfilling the EFNS/PNS diagnostic
criteria12 and 29 controls with noninflammatory neuro-
logical disease conditions were included in the analysis
(Table 1). All patients underwent neurological examina-
tion at the time of diagnosis, serum and CSF were col-
lected before induction of immunomodulatory therapy
with intravenous immunoglobulin (2 g/kg body weight
over 5 consecutive days) and patients were re-examined
after 4 weeks. Complement activation can be triggered
by various stimuli including immune complexes, extra-
cellular matrix proteins and apoptotic/necrotic cells17.
Complement activating pathways converge to the gen-
eration of the anaphylatoxin C5a and the TCC, gener-
ated by the assembly of C5b through C9. The C5b-9
that fails to assemble in the membrane forms a soluble,
lytically inert complex, termed sTCC, and complement-
mediated cell lysis was shown to closely correlate with
the generation of sTCC levels in vitro.16 Here, terminal
complement activation was quantified in serum and
CSF samples by ELISAs specific for C5a and sTCC.
Compared to controls, patients with CIDP showed sig-
nificantly higher levels of C5a and sTCC in both serum


















































































Figure 1. Increased terminal complement activation in serum and CSF of CIDP patients. Shown are (A) serum and (B) CSF levels of C5a, sTCC
and albumin in treatment-na€ıve patients with CIDP compared to patients with noninflammatory neurological diseases (controls). Statistics were
performed by Mann–Whitney U test. CIDP, Chronic inflammatory demyelinating polyneuropathy; sTCC, soluble terminal complement complex.
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95.6 ng/mL were exclusively observed in patients with
CIDP. We additionally analyzed C5a and sTCC serum
levels in patients with SLE receiving immunomodulatory
therapy (Table 1). Compared to patients with CIDP,
patients with SLE showed lower levels of C5a (mean:
43.18 ng/mL, SD: 22.68; P < 0.0001) and sTCC (mean:
2782 ng/mL, SD: 1533; P < 0.0001). Increased levels of
C5a and sTCC in CSF samples of CIDP patients corre-
lated with CSF albumin concentrations (sTCC: r = 0.82,
P = 0.0001; C5a: r = 0.77, P < 0.0001) and CSF indices
for C5a and TCC were lower in patients with CIDP
compared to controls (P < 0.0001 for C5a and
P < 0.012 for sTCC) suggesting a systemic increase of
terminal complement activation as opposed to local
production within the CSF compartment. Serum levels
of albumin, chosen as control protein, were unchanged
in patients with CIDP (Fig. 1). Thus, systemic terminal
complement activation as reflected by C5a and sTCC
and levels is increased in treatment-na€ıve patients with
CIDP.
We next investigated whether increased terminal com-
plement activation is associated with or anticipates clini-
cal disease severity in patients with CIDP. Disease severity
was monitored using the INCAT (Inflammatory Neuropa-
thy Cause and Treatment) disability score 14,15 during the
diagnostic workup and 4 weeks after initiation of IVIG
therapy. INCAT disability scores were reduced in 16/21
(80%) patients 4 weeks after IVIG therapy induction.
Both C5a and sTCC levels tended to be higher in patients
with higher disability at the time of diagnosis (Fig. 2A)
and significantly correlated with INCAT scores deter-
mined at 4 week follow-up visits (Fig. 2B). No significant
correlation could be observed for clinical disease severity
and albumin concentrations (Fig. 2). CSF levels of C5a
and TCC at the initial presentation did not significantly
correlate with INCAT disability scores at any time point
(data not shown). Thus, systemic terminal complement
activation is associated with residual disease severity




































































































Figure 2. Systemic terminal complement activation correlates with disease severity in patients with CIDP. Shown are Spearman’s rank correlation
analyses of serum C5a, sTCC and albumin levels with disease severity (defined by INCAT score) of (A) newly diagnosed, previously untreated
patients with CIDP and (B) 4 weeks after immunomodulatory therapy with IVIG (2 g/kg body weight over 5 consecutive days). Each dot reflects
an individual patient. Displayed are linear regression curves. Statistics were performed by Spearman test. CIDP, Chronic inflammatory
demyelinating polyneuropathy; INCAT, Inflammatory Neuropathy Cause and Treatment; sTCC, soluble terminal complement complex.
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Discussion
Our study demonstrates that systemic terminal comple-
ment activation as defined by serum C5a and TCC levels
is increased and associated with disease severity in
patients with CIDP. Sera from CIDP patients which,
upon adoptive transfer, induced conduction block and
demyelination in rat sciatic nerves show IgG and C3d
binding to myelin components on normal peripheral
nerve tissue, indicating that their demyelinating capacity
is antibody-mediated and complement-dependent.6 Our
data suggest that systemic and local terminal complement
activation is a characteristic feature of inflammatory
demyelinating polyneuropathies and support a role of
complement activation in the pathogenesis of CIDP.
Deficiencies of early components of the classical com-
plement activation pathway such as C1q, C2, and C4 are
strongly associated with the development of SLE, presum-
ably due to impaired complement-mediated clearance of
dying cells,17 and low concentrations of complement
components are observed in a majority of patients with
active and severe SLE. In contrast, terminal complement
activation products such as C5a and sTCC, although
reported to correlate with clinical disease activity in indi-
vidual patients, are either normal or only slightly elevated
in sera from patients with established SLE.18,19 The find-
ing that C5a and sTCC levels are substantially higher in
patients with CIDP compared to SLE suggest differential
mechanisms and functions of terminal complement acti-
vation in these diseases, although treatment-related effects
cannot be excluded since all SLE patients included in our
study received immunomodulatory therapy.
Terminal complement activation can be inhibited thera-
peutically, for example, by eculizumab, a humanized mon-
oclonal antibody which blocks the cleavage from C5 to C5a
and C5b, thereby preventing the generation of C5a and
TCC formation. Eculizumab is approved for the treatment
of paroxysmal nocturnal hemoglobinuria and atypical
hemolytic uremic syndrome, was shown to be therapeuti-
cally effective in a murine model of acute antibody-
mediated neuropathy20 and is currently tested for its safety
and efficacy in patients with GBS. In an open-label clinical
trial conducted in 13 patients with multifocal motor neu-
ropathy (MMN), eculizumab treatment did not show
objective clinical benefits, although improvement of some
secondary outcomes such as patient-rated subjective scores
and selected clinical and electrophysiological measurements
were reported.21 Our data strongly indicate that inhibition
of terminal complement activation should be explored for
its potential therapeutic merit in patients with CIDP.
There are limitations to our study. First, the relatively
small number of patients requires validation in larger
independent cohorts. Second, we did not monitor serum
C5a and TCC levels over time in order to investigate
whether terminal complement activation remains
increased during disease progression and under
immunomodulatory therapy since transient reduction of
complement proteins and/or complement activation occur
after plasmapheresis,22 during corticosteroid therapy23 as
well as following IVIG treatment,24. A small open-label
clinical trial on eculizumab in patients with MMN who
concomitantly received IVIG reported that most patients
continued to require IVIG despite full inhibition of termi-
nal complement function 21 suggesting that the therapeu-
tic efficacy of IVIG is mediated by immunomodulatory
mechanisms other than complement inhibition. Further-
more, our study was restricted to patients with ideopathic
or typical CIDP characterized by symmetrical, proximal
and distal sensory and motor deficits which comprise
only 50–60% of patients with CIDP.1,2,7 Our findings,
however, provide incentive to conduct larger prospective
investigations to examine terminal complement activation
as a potential surrogate marker for clinical disease activ-
ity, progression, and response to immunomodulatory
therapies in patients with major phenotypic variants of
CIDP. It remains to be evaluated whether inhibition of
terminal complement activation can be harnessed to
improve the clinical outcome in patients with CIDP.
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